Shares of Biopharmx Corp (NYSE:BPMX) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price target of $3.38 for the company and are expecting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Biopharmx Corp an industry rank of 108 out of 265 based on the ratings given to related companies.

Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 24th.

TRADEMARK VIOLATION NOTICE: “Brokerages Set $3.38 Price Target for Biopharmx Corp (NYSE:BPMX)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/brokerages-set-3-38-price-target-for-biopharmx-corp-nysebpmx.html.

Shares of Biopharmx Corp (NYSE BPMX) opened at 0.2917 on Tuesday. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $1.22. The firm’s market capitalization is $21.62 million. The firm’s 50-day moving average is $0.44 and its 200 day moving average is $0.51.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.